Uric acid and chronic kidney disease: Which is chasing which?

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2221-2228

  Johnson, Richard J ^a   Nakagawa, Takahiko ^b   Jalal, Diana ^a   Sánchez Lozada, Laura Gabriela ^c   Kang, Duk Hee ^d   Ritz, Eberhard ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c Laboratory of Renal Physiopathology and Department of Nephrology   (Mexico)

^d Ewha Womans University School of Medicine   (South Korea)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Allopurinol; Chronic kidney disease; Gout; Hyperuricemia; Uric acid

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; LOSARTAN; PLACEBO; URIC ACID;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CRYSTAL; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL STUDY; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS (TOPIC); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CHRONIC KIDNEY DISEASE; GOUT; HYPERURICEMIA; URIC ACID;

ANIMALS; HUMANS; RATS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; URIC ACID;

EID: 84882925526     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft029     Document Type: Review

References (82)

1. Johnson G. On the Diseases of the Kidney. London: John W Parker and Son; 1852
2. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore) 1960; 39: 405-467
3. Barlow KA, Beilin LJ. Renal disease in primary gout. Q J Med 1968; 37: 79-96
4. Yu TF, Berger L. Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease. Am J Med 1982; 72: 95-100
5. Johnson RJ, Kivlighn SD, Kim YG et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-234
6. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897
7. Sanchez-Lozada LG, Soto V, Tapia E et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol 2008; 295: F1134-F1141
8. Sanchez-Lozada LG, Tapia E, Lopez-Molina R et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol 2007; 292: F1238-F1244
9. Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247
10. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106
11. Nakagawa T, Mazzali M, Kang DH et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2-7
12. Ryu E-S, Kim MJ, Shin H-S et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol 2013; 304: F471-80
13. Kosugi T, Nakayama T, Heinig M et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009; 297: F481-F488
14. Mazzali M, Kim YG, Suga S et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900-905
15. Mazali FC, Johnson RJ, Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. Nephron Exp Nephrol 2012; 120: e12-e19
16. Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012; 121: e71-e78
17. Rabadi MM, Kuo MC, Ghaly T et al. Interaction between uric acid and HMGB1 translocation and release from endothelial cells. Am J Physiol 2012; 302: F730-F741
18. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
19. Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275
20. Zhou Y, Fang L, Jiang L et al. Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS ONE 2012; 7: e39738
21. Johnson RJ, Perez-Pozo SE, Sautin YY et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009; 30: 96-116
22. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
23. Suliman ME, Johnson RJ, Garcia-Lopez E et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48: 761-771
24. Madero M, Sarnak MJ, Wang X et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53: 796-803
25. Sturm G, Kollerits B, Neyer U et al. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol 2008; 43: 347-352
26. Altemtam N, Russell J, El Nahas M. A study of the natural history of diabetic kidney disease (DKD). Nephrol Dial Transplant 2012; 27: 1847-1854
27. Shi Y, Chen W, Jalal D et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 2012; 35: 153-160
28. Ohno I, Hosoya T, Gomi H et al. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001; 87: 333-339
29. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42
30. Shi Y, Chen W, Jalal D et al. Clinical outcome of hyperuricemia in IgA nephropathy: a Retrospective Cohort Study and Randomized Controlled Trial. Kidney Blood Press Res 2011; 35: 153-160
31. Wu J, Chen X, Xie Y et al. Characteristics and risk factors of intrarenal arterial lesions in patients with IgA nephropathy. Nephrol Dial Transplant 2005; 20: 719-727
32. Akalin E, Ganeshan SV, Winston J et al. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation 2008; 86: 652-658
33. Bo S, Cavallo-Perin P, Gentile L et al. Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes. Eur J Clin Invest 2001; 31: 318-321
34. Hovind P, Rossing P, Tarnow L et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668-1671
35. Jalal DI, Rivard CJ, Johnson RJ et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010; 25: 1865-1869
36. Ficociello LH, Rosolowsky ET, Niewczas MA et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-1343
37. Zoppini G, Targher G, Chonchol M et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes care 2012; 35: 99-104
38. Kohagura K, Kochi M, Miyagi T et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 2013; 36: 43-49
39. Kanbay M, Yilmaz MI, Sonmez A et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 2012; 36: 324-331
40. Ito H, Abe M, Mifune M et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS ONE 2011; 6: e27817
41. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002; 282: F991-F997
42. Lee SM, Lee AL, Winters TJ et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol 2009; 29: 79-85
43. Quinones GA, Natali A, Baldi S et al. Effect of insulin on uric acid excretion in humans. The Am J Physiol 1995; 268: E1-E5
44. Messerli FH, Frohlich ED, Dreslinski GR et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Int Med 1980; 93: 817-821
45. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247-252
46. Choi HK, Atkinson K, Karlson EW et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-1103
47. Malik VS, Popkin BM, Bray GA et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a metaanalysis. Diabetes Care 2010; 33: 2477-2483
48. Lin WT, Huang HL, Huang MC et al. Effects on uric acid, body mass index and blood pressure in adolescents of consuming beverages sweetened with high-fructose corn syrup. Int J Obes (Lond) 2012. doi: 10.1038/ijo.2012.121. [Epub ahead of print]
49. Nguyen S, Choi HK, Lustig RH et al. Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents. J Pediatr 2009; 154: 807-813
50. Shoham DA, Durazo-Arvizu R, Kramer H et al. Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999-2004. PLoS ONE 2008; 3: e3431
51. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol 2008; 294: F710-F718
52. Nakagawa T, Hu H, Zharikov S et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol 2006; 290: F625-F631
53. Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Int Med 1999; 130: 7-13
54. Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 1978; 124: 65-76
55. Roncal C, Mu W, Reungjui S et al. Lead, at low levels, accelerates arteriolopathy and tubulointerstitial injury in chronic kidney disease. Am J Physiol 2007; 293: F1391-F1396
56. Chang FM, Chow SN, Huang HC et al. The placental transfer and concentration difference in maternal and neonatal serum uric acid at parturition: comparison of normal pregnancies and gestosis. Biol Res Pregnancy Perinatol 1987; 8: 35-39
57. Franco MC, Christofalo DM, Sawaya AL et al. Effects of low birth weight in 8-to 13-year-old children: implications in endothelial function and uric acid levels. Hypertension 2006; 48: 45-50
58. Park B, Park E, Cho SJ et al. The association between fetal and postnatal growth status and serum levels of uric acid in children at 3 years of age. Am J Hypertens 2009; 22: 403-408
59. Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66: 281-287
60. Schaffer P, Gombos E, Meichelbeck K et al. Childhood course of renal insufficiency in a family with a uromodulin gene mutation. Pediatr Nephrol 2010; 25: 1355-1360
61. Fairbanks LD, Cameron JS, Venkat-Raman G et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM 2002; 95: 597-607
62. Kottgen A, Glazer NL, Dehghan A et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nature Genetics 2009; 41: 712-717
63. Han J, Liu Y, Rao F et al. Common genetic variants of the human UMOD gene are functional on transcription and predict plasma uric acid in two distinct populations. Kidney Int 2013 (in press)
64. McAdams-Demarco MA, Maynard JW et al. A urate gene-bydiuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann Rheum Dis
65. Lai JY, Atzmon G, Melamed ML et al. Family history of exceptional longevity is associated with lower serum uric acid levels in Ashkenazi Jews. J Am Geriatr Soc 2012; 60: 745-750
66. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59
67. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393
68. Momeni A, Shahidi S, Seirafian S et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 2010; 4: 128-132
69. Wang H, Wei Y, Kong X et al. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr 2013 (in press)
70. Ito S, Naritomi H, Ogihara T et al. Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertens Res 2012; 35: 867-873
71. Yu MA, Sanchez-Lozada LG, Johnson RJ et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28: 1234-1242
72. Saito I, Saruta T, Kondo K et al. Serum uric acid and the reninangiotensin system in hypertension. J Am Geriatr Soc 1978; 26: 241-247
73. Perlstein TS, Gumieniak O, Hopkins PN et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int 2004; 66: 1465-1470
74. Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27: 435-440
75. Roncal CA, Reungjui S, Sanchez-Lozada LG et al. Combination of captopril and allopurinol retards fructose-induced metabolic syndrome. Am J Nephrol 2009; 30: 399-404
76. Miao Y, Ottenbros SA, Laverman GD et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2-7
77. Smink PA, Bakker SJ, Laverman GD et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post hoc analysis of the RENAAL and IDNT trials. J Hypertens 2012; 30: 1022-1028
78. Jung JW, Song WJ, Kim YS et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 3567-3572
79. Naoyuki K, Shin F, Toshikazu H et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol 2011; 17: S44-S49
80. Schumacher HR, Jr., Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548
81. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63
82. Beck LH. Requiem for gouty nephropathy. Kidney Int 1986; 30: 280-287